Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis

Mohamad Mohty, Nabih Azar, Christian Chabannon, Steven Le Gouill, Lionel Karlin, Lucia Farina, Gary Milkovich, Helmut Ostermann, Bertram Glaß, Richard Noppeney, Florian Kron, Anna Kron, Kai Hübel

Research output: Contribution to journalArticlepeer-review


High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal of PBSC mobilization is to allow collection of sufficient CD34+ cells to proceed to transplantation. The current mobilization regimen with granulocyte colony-stimulating factor (G-CSF), alone or in combination with chemotherapy, still fails in 10-25% of patients. Plerixafor is able to rescue most of these patients from mobilization failure. In this study, we investigated the impact of plerixafor on the cost and time spent on apheresis in patients who were considered poor mobilizers, with <20 × 106/µl peripheral CD34+ cells after mobilization but prior to apheresis. Patient hospital records from ten centers in three European countries were reviewed and compared during two time periods, namely prior and after plerixafor introduction to the market. During the plerixafor period, patients spent less time on apheresis (350 vs. 461  min). Poor mobilizers given plerixafor collected more CD34+ cells during the first apheresis session, leading to a decrease in the average number of apheresis sessions needed. The total apheresis yield was unaffected. This analysis shows that the use of plerixafor lessens the time-effort associated with the management of poor mobilizers and reduces apheresis costs.

Original languageEnglish
Pages (from-to)246-254
Number of pages9
JournalBone Marrow Transplantation
Issue number3
Publication statusPublished - Mar 2018


Dive into the research topics of 'Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis'. Together they form a unique fingerprint.

Cite this